Tag «type 2 diabetes»

It’s only fair to share…   DAPAGLIFLOZIN, BMS-512148 ダパグリフロジン; (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol, Cas 461432-26-8 Molecular Formula: C21H25ClO6 Molecular Weight: 408.87 Dapagliflozin propandiol monohydrate; 960404-48-2 Molecular Weight 502.98 Formula C21H25ClO6•C3H8O2•H2O Bristol-Myers Squibb (Originator) AstraZeneca TYPE 2 DIABETES,SGLT-2 Inhibitors launched 2012,  as forxiga in EU, FDA 2014, JAPAN PMDA 2014 Dapagliflozin propanediol monohydrate was first approved by European Medicine Agency (EMA) on November 12, …

Read more

It’s only fair to share…   Enavogliflozin, DWP-16001 (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-cyclopropylbenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (2S,3R,4R,5S,6R)-2-(7-chloro-6-(4-cyclopropylbenzyl)-2,3-dihydrobenzofuran-4-yl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol CAS: 1415472-28-4 Chemical Formula: C24H27ClO6 Molecular Weight: 446.92 Elemental Analysis: C, 64.50; H, 6.09; Cl, 7.93; O, 21.48 Green Cross Corp INNOVATOR Daewoong Pharmaceutical Co Ltd Enavogliflozin is an antidiabetic (hypoglycemic). Daewoong is investigating DWJ-304 , a sodium/glucose cotransporter 2 (SGLT-2) inhibitor, for treating type …

Read more

It’s only fair to share…     SY-008 CAS 1878218-66-6 FREE FORM 1480443-32-0 SGLT1 inhibitor (type 2 diabetes), β-D-Glucopyranoside, 4-[[4-[(1E)-4-(2,9-diazaspiro[5.5]undec-2-yl)-1-buten-1-yl]-2-methylphenyl]methyl]-5-(1-methylethyl)-1H-pyrazol-3-yl, acetate (1:1) acetic acid;(2S,3R,4S,5S,6R)-2-[[4-[[4-[(E)-4-(2,9-diazaspiro[5.5]undecan-2-yl)but-1-enyl]-2-methylphenyl]methyl]-5-propan-2-yl-1H-pyrazol-3-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol 4-{4-[(1E)-4-(2,9-diazaspiro[5.5]undec-2-yl)but-1-en-1-yl]-2-methylbenzyl}-5-(propan-2-yl)-1H-pyrazol-3-yl beta-D-glucopyranoside acetate MF H50 N4 O6 . C2 H4 O2 MW 58.8 g/mol,C35H54N4O8 Originator Eli Lilly Developer Eli Lilly; Yabao Pharmaceutical Group Class Antihyperglycaemics; Small molecules Mechanism of Action Sodium-glucose transporter 1 inhibitors Phase I Diabetes mellitus 28 Aug 2018 No recent reports of …

Read more

It’s only fair to share…   ASP ? (2R)-2-(4-cyclopropanesulfonyl-3-cyclopropylphenyl)-N-[5-(hydroxymethyl)pyrazin-2-yl]-3-[(R)-3-oxocyclopentyl]propanamide CAS 1174229-89-0 MW C25 H29 N3 O5 S Benzeneacetamide, 3-cyclopropyl-4-(cyclopropylsulfonyl)-N-[5-(hydroxymethyl)-2-pyrazinyl]-α-[[(1R)-3-oxocyclopentyl]methyl]-, (αR)- Molecular Weight, 483.58 [α]D20 −128.7 (c 1.00, MeOH); 1H NMR (DMSO-d6, 400 MHz) δ 11.07 (s, 1H), 9.20 (d, J = 1.4 Hz, 1H), 8.41 (d, J = 1.4 Hz, 1H), 7.79 (d, J = 8.2 …

Read more

It’s only fair to share… AMG-3969 M.Wt: 522.46 Cas : 1361224-53-4 , MF: C21H20F6N4O3S WO 2012027261 PRODUCT PATENT Inventors Kate Ashton, Michael David Bartberger, Yunxin Bo, Marian C. Bryan, Michael Croghan, Christopher Harold Fotsch, Clarence Henderson Hale, Roxanne Kay Kunz, Longbin Liu, Nobuko Nishimura, Mark H. Norman, Lewis Dale Pennington, Steve Fong Poon, Markian Myroslaw Stec, Jean …

Read more

It’s only fair to share… BMS-741672 N-((1R,2S,5R)-5-(Isopropyl(methyl)amino)-2-((S)-2-oxo-3-(6-(trifluoromethyl)quinazolin-4-ylamino)pyrrolidin-1-yl)cyclohexyl)acetamide BMS-741672 N-((lR,2S,5R)-5-(isopropyl(methyl)amino)-2-((S)-2-oxo-3-(6- (trifluoromethyl)quinazolin-4-ylamino)pyrrolidin-l-yl)cyclohexyl)acetamide N-((1R,2S,5R)-5-(isopropyl(methyl)amino)-2-((S)-2-oxo-3-(6-(trifluoromethyl)quinazolin-4-ylamino)pyrrolidin-1-yl)cyclohexyl)acetamide; C25 H33 F3 N6 O2, 506.56 Acetamide, N-[(1R,2S,5R)-5-[methyl(1-methylethyl)amino]-2-[(3S)-2-oxo-3-[[6-(trifluoromethyl)-4-quinazolinyl]amino]-1-pyrrolidinyl]cyclohexyl]- CAS 1004757-96-3 PHASE 2, , Treatment of Type 2 Diabetes, Agents for Neuropathic Pain Chemokine CCR2 (MCP-1 Receptor) Antagonists Molecular Formula: C25H33F3N6O2 Molecular Weight: 506.574 g/mol Michael G. Yang, Robert J. Cherney Original Assignee Bristol-Myers Squibb Company Michael G. Yang, …

Read more

It’s only fair to share… Indian flag (S)-3-(4-((3-((isopropyl(thiophen-3- ylmethyl)amino)methyl)benzyl)oxy)phenyl)hex-4-ynoic acid Calcium (S)-3-(4-((3-((isopropyl(thiophen-3-yl methyl)amino)methyl)benzyl)oxy)phenyl)hex-4-ynoate Calcium (S)-3-(4-((3-((isopropyl(thiophen-3-yl methyl)amino)methyl)benzyl)oxy)phenyl)hex-4-ynoate   The compounds of theese type lower blood glucose, regulate peripheral satiety, lower or modulate triglyceride levels and/or cholesterol levels and/or low-density lipoproteins (LDL) and raises the high-density l ipoproteins (HDL) plasma levels and hence are useful in combating different …

Read more

It’s only fair to share… REMOGLIFLOZIN ETABONATE 5-methyl-4-[4-(1-methylethoxy)benzyl]-1-(1-methylethyl)-1H-pyrazol-3-yl 6-O-(ethoxycarbonyl)-β-D-glucopyranoside, ethyl [(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[5-methyl-1-propan-2-yl-4-[(4-propan-2-yloxyphenyl)methyl]pyrazol-3-yl]oxy-oxan-2-yl]methyl carbonate  https://clinicaltrials.gov/show/NCT02537470   UNII:TR0QT6QSUL CAS 442201-24-3 189075  BHV-091009  GSK-189075  GSK-189075A  KGT-1681  BHV Pharma  Kissei (Originator)  , GlaxoSmithKline Remogliflozin etabonate Phase II A SGLT-2 antagonist potentially for the treatment of type 2 diabetes, non-alcoholic steatohepatitis (NASH), obesity. GSK-189075; GSK-189075A Molecular FormulaC26H38N2O9 Average mass522.588 Remogliflozin etabonate (INN/USAN)[1] …

Read more